AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 71 min read$NEO

NeoGenomics, Inc. (NEO) Stock Forecasts

Argus lowered its target price for NeoGenomics Inc. (NEO) to $17.00. The company offers oncology diagnostic testing and consultative services. NEO provides technical lab services and professional interpretation of test results by licensed physicians or molecular experts in pathology and oncology.

Original reporting
finance.yahoo.com
Published Oct 7, 2026, 10:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:15 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$NEO
Bearish
medium confidence
Mentioned
$NEO
Relevance
6/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$NEOBearishMed
01

Why it matters

The target price reduction reflects analyst concerns and could trigger short‑term selling pressure.

02

Market read

A modest analyst downgrade for a micro‑cap biotech, limited broader market effect.

03

What to watch

Potential upcoming product launches or contract wins not reflected in the target price.

Relevance 6/10Novelty 7/10Timing: today

Background

NeoGenomics provides oncology diagnostic testing and consultative services.

Company-level read

Ticker impact

$NEOBearishMedium confidence
Context

Analyst lowered NeoGenomics' target price to $17.00.

Expected impact

likely downward pressure as investors price in lower valuation

Evidence & confidence

A lower target suggests concerns about growth or earnings, prompting sellers.

Market effects

Sector

May affect other oncology diagnostics firms as valuation benchmarks shift.

Regional

Limited to U.S. biotech and healthcare investors.

Global

Low global impact; primarily a U.S. micro‑cap event.

Counterpoint

What could challenge this read

Some investors may view the cut as an overreaction and see buying opportunity.

Key entities

  • company
    NeoGenomics, Inc.

    Oncology diagnostics provider.

Read at source← All news

Related articles

OCT 7
$NEOMed

Piper Sandler reiterates Neogenomics stock rating on service strength

Piper Sandler reiterated an Overweight rating on Neogenomics (NEO), citing its competitive position in the community oncology lab market. The firm highlighted the company's service and menu offerings, with NEO ranking first in menu completeness, turnaround, and service. NEO's stock has fallen 10% to $16.42, despite an 83% return over the past year. Recent earnings exceeded expectations, with adjusted earnings of $0.05 per share and revenue of $202 million.

investing.com2 min
OCT 6
$NEOMed

Why NeoGenomics (NEO) Stock Is Up Today

NeoGenomics (NEO) shares rose 3.6% premarket after announcing an executive succession plan and preliminary Q3 revenue of $209M, with next-gen sequencing revenue up 28% YoY. The company expects to raise full-year guidance. BTIG upgraded NEO to Buy with a $28 price target. Shares later fell to $17.36, down 9.1% from the previous close.

financialcontent.com2 min
OCT 6
$LENHighAI 8/10

Stocks making the biggest moves premarket: Constellation Energy, Option Care Health, Lennar, P&G and more

Constellation Energy (CEG) surged 6% after Google's $4.3B power agreement. Option Care Health (OPK) rose 20% on potential $5B acquisition by McKesson (MCK) and Clayton Dubilier. Lennar (LEN) gained 1.5% after Berkshire Hathaway (BRK.A) disclosed a 2.4M share purchase. NeoGenomics (NEO) climbed 5% on revenue beat and succession plan. AMD (AMD) rose 2% on Citi's $800 price target. P&G (PG) up 1.2% after Evercore ISI upgrade. Corteva (CTVA) gained 3% on JPMorgan upgrade.

cnbc.com2 min